These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
Pubmed for Handhelds
PUBMED FOR HANDHELDS
Journal Abstract Search
1009 related items for PubMed ID: 30826284
1. Modelling Study with an Interactive Model Assessing the Cost-effectiveness of 68Ga Prostate-specific Membrane Antigen Positron Emission Tomography/Computed Tomography and Nano Magnetic Resonance Imaging for the Detection of Pelvic Lymph Node Metastases in Patients with Primary Prostate Cancer. Scholte M, Barentsz JO, Sedelaar JPM, Gotthardt M, Grutters JPC, Rovers MM. Eur Urol Focus; 2020 Sep 15; 6(5):967-974. PubMed ID: 30826284 [Abstract] [Full Text] [Related]
2. Distribution of prostate cancer recurrences on gallium-68 prostate-specific membrane antigen (68 Ga-PSMA) positron-emission/computed tomography after radical prostatectomy with pathological node-positive extended lymph node dissection. Huits TH, Luiting HB, van der Poel HG, Nandurkar R, Donswijk M, Schaake E, Vogel W, Roobol MJ, Wit E, Stricker P, Emmett L, van Leeuwen PJ. BJU Int; 2020 Jun 15; 125(6):876-883. PubMed ID: 32181951 [Abstract] [Full Text] [Related]
3. Histological comparison between predictive value of preoperative 3-T multiparametric MRI and 68 Ga-PSMA PET/CT scan for pathological outcomes at radical prostatectomy and pelvic lymph node dissection for prostate cancer. Franklin A, Yaxley WJ, Raveenthiran S, Coughlin G, Gianduzzo T, Kua B, McEwan L, Wong D, Delahunt B, Egevad L, Samaratunga H, Brown N, Parkinson R, Roberts MJ, Yaxley JW. BJU Int; 2021 Jan 15; 127(1):71-79. PubMed ID: 32524748 [Abstract] [Full Text] [Related]
4. More advantages in detecting bone and soft tissue metastases from prostate cancer using 18F-PSMA PET/CT. Pianou NK, Stavrou PZ, Vlontzou E, Rondogianni P, Exarhos DN, Datseris IE. Hell J Nucl Med; 2019 Jan 15; 22(1):6-9. PubMed ID: 30843003 [Abstract] [Full Text] [Related]
5. Comparison of 68Ga-PSMA-11 PET-CT with mpMRI for preoperative lymph node staging in patients with intermediate to high-risk prostate cancer. Zhang Q, Zang S, Zhang C, Fu Y, Lv X, Zhang Q, Deng Y, Zhang C, Luo R, Zhao X, Wang W, Wang F, Guo H. J Transl Med; 2017 Nov 07; 15(1):230. PubMed ID: 29115970 [Abstract] [Full Text] [Related]
6. 68Ga-PSMA PET/CT based primary staging and histological correlation after extended pelvic lymph node dissection at radical prostatectomy. Kopp J, Kopp D, Bernhardt E, Manka L, Beck A, Gerullis H, Karakiewicz P, Schoerner W, Hammerer P, Schiffmann J. World J Urol; 2020 Dec 07; 38(12):3085-3090. PubMed ID: 32103332 [Abstract] [Full Text] [Related]
7. Incremental Impact of [68 Ga]Ga-PSMA-11 PET/CT in Primary N and M Staging of Prostate Cancer Prior to Curative-Intent Surgery: a Prospective Clinical Trial in Comparison with mpMRI. Szigeti F, Schweighofer-Zwink G, Meissnitzer M, Hauser-Kronberger C, Hitzl W, Kunit T, Forstner R, Pirich C, Beheshti M. Mol Imaging Biol; 2022 Feb 07; 24(1):50-59. PubMed ID: 34519966 [Abstract] [Full Text] [Related]
8. Can Negative Prostate-specific Membrane Antigen Positron Emission Tomography/Computed Tomography Avoid the Need for Pelvic Lymph Node Dissection in Newly Diagnosed Prostate Cancer Patients? A Systematic Review and Meta-analysis with Backup Histology as Reference Standard. Stabile A, Pellegrino A, Mazzone E, Cannoletta D, de Angelis M, Barletta F, Scuderi S, Cucchiara V, Gandaglia G, Raggi D, Necchi A, Karakiewicz P, Montorsi F, Briganti A. Eur Urol Oncol; 2022 Feb 07; 5(1):1-17. PubMed ID: 34538770 [Abstract] [Full Text] [Related]
9. How accurate is 68Gallium-prostate specific membrane antigen positron emission tomography / computed tomography (68Ga-PSMA PET/CT) on primary lymph node staging before radical prostatectomy in intermediate and high risk prostate cancer? A study of patient- and lymph node- based analyses. Erdem S, Simsek DH, Degirmenci E, Aydin R, Bagbudar S, Ozluk Y, Sanli Y, Sanli O, Ozcan F. Urol Oncol; 2022 Jan 07; 40(1):6.e1-6.e9. PubMed ID: 34400066 [Abstract] [Full Text] [Related]
10. Outcomes of Primary Lymph Node Staging of Intermediate and High Risk Prostate Cancer with 68Ga-PSMA Positron Emission Tomography/Computerized Tomography Compared to Histological Correlation of Pelvic Lymph Node Pathology. Yaxley JW, Raveenthiran S, Nouhaud FX, Samartunga H, Yaxley AJ, Coughlin G, Delahunt B, Egevad L, McEwan L, Wong D. J Urol; 2019 Apr 07; 201(4):815-820. PubMed ID: 30672842 [Abstract] [Full Text] [Related]
11. 68Ga-PSMA Positron Emission Tomography/Computed Tomography Provides Accurate Staging of Lymph Node Regions Prior to Lymph Node Dissection in Patients with Prostate Cancer. Herlemann A, Wenter V, Kretschmer A, Thierfelder KM, Bartenstein P, Faber C, Gildehaus FJ, Stief CG, Gratzke C, Fendler WP. Eur Urol; 2016 Oct 07; 70(4):553-557. PubMed ID: 26810345 [Abstract] [Full Text] [Related]
12. PSMA PET Scan Era: A Changing Paradigm PSMA PET and Lymph Node Dissection for Prostate Cancer Management. Haxhimolla J, Kua B, Gilbourd D, Haxhimolla H. Semin Oncol Nurs; 2020 Aug 07; 36(4):151044. PubMed ID: 32723519 [Abstract] [Full Text] [Related]
13. Head-to-Head Comparison of 68Ga-Prostate-Specific Membrane Antigen PET/CT and Ferumoxtran-10-Enhanced MRI for the Diagnosis of Lymph Node Metastases in Prostate Cancer Patients. Schilham MGM, Zamecnik P, Privé BM, Israël B, Rijpkema M, Scheenen T, Barentsz JO, Nagarajah J, Gotthardt M. J Nucl Med; 2021 Sep 01; 62(9):1258-1263. PubMed ID: 33517328 [Abstract] [Full Text] [Related]
14. 68Ga-Labeled Prostate-specific Membrane Antigen Ligand Positron Emission Tomography/Computed Tomography for Prostate Cancer: A Systematic Review and Meta-analysis. von Eyben FE, Picchio M, von Eyben R, Rhee H, Bauman G. Eur Urol Focus; 2018 Sep 01; 4(5):686-693. PubMed ID: 28753806 [Abstract] [Full Text] [Related]
15. Identification of the Optimal Candidates for Nodal Staging with Extended Pelvic Lymph Node Dissection Among Prostate Cancer Patients Who Underwent Preoperative Prostate-specific Membrane Antigen Positron Emission Tomography. External Validation of the Memorial Sloan Kettering Cancer Center and Briganti Nomograms and Development of a Novel Tool. Gandaglia G, Barletta F, Robesti D, Scuderi S, Rajwa P, Gomez Rivas J, Ibanez L, Soeterik TFW, Bianchi L, Afferi L, Kesch C, Darr C, Guo H, Zhuang J, Zattoni F, Fendler W, Marra G, Stabile A, Amparore D, Huebner NA, Giesen A, Joniau S, Schiavina R, Brunocilla E, Mattei A, Dal Moro F, Sierra JM, Porpiglia F, Picchio M, van den Bergh R, Shariat SF, Montorsi F, Briganti A. Eur Urol Oncol; 2023 Dec 01; 6(6):543-552. PubMed ID: 37270378 [Abstract] [Full Text] [Related]
16. The diagnostic accuracy of 68 Ga-PSMA-PET/CT in primary staging of patients with high-risk nonmetastatic prostate cancer treated with radical prostatectomy: A single-center cohort analysis. Rajwa P, Heidenreich J, Drzezga A, Schmidt M, Shariat SF, Heidenreich A. Prostate; 2024 Jan 01; 84(1):74-78. PubMed ID: 37750292 [Abstract] [Full Text] [Related]
17. Comparison of preoperative locoregional Ga-68 PSMA-11 PET-CT and mp-MRI results with postoperative histopathology of prostate cancer. Yilmaz B, Turkay R, Colakoglu Y, Baytekin HF, Ergul N, Sahin S, Tugcu V, Inci E, Tasci AI, Cermik TF. Prostate; 2019 Jun 01; 79(9):1007-1017. PubMed ID: 31012125 [Abstract] [Full Text] [Related]
18. Ga68-PSMA PET for lymph node staging in intermediate and high-risk prostate cancer patients undergoing robotic assisted radical prostatectomy. Spena G, Moretti TB, Dávila FS, Dos Anjos G, Khan I, Calace FP, Aveta A, Pandolfo SD, Tufano A, Izzo A, Farias A, Perdonà S, Maes K. Minerva Urol Nephrol; 2024 Aug 01; 76(4):467-473. PubMed ID: 39051893 [Abstract] [Full Text] [Related]
19. In primary lymph nodal staging of patients with high-risk and intermediate-risk prostate cancer, how critical is the role of Gallium-68 prostate-specific membrane antigen positron emission tomography-computed tomography? Kulkarni SC, Sundaram PS, Padma S. Nucl Med Commun; 2020 Feb 01; 41(2):139-146. PubMed ID: 31714366 [Abstract] [Full Text] [Related]
20. 68Ga-PSMA-11 PET has the potential to improve patient selection for extended pelvic lymph node dissection in intermediate to high-risk prostate cancer. Ferraro DA, Muehlematter UJ, Garcia Schüler HI, Rupp NJ, Huellner M, Messerli M, Rüschoff JH, Ter Voert EEGW, Hermanns T, Burger IA. Eur J Nucl Med Mol Imaging; 2020 Jan 01; 47(1):147-159. PubMed ID: 31522272 [Abstract] [Full Text] [Related] Page: [Next] [New Search]